항정신병약물 치료에 부분적인 반응을 보인 조현병 환자에 대한 아미설프라이드 병용요법의 효과와 안전성에 관한 연구

키워드

참고문헌 (45)

1. Seung-Gul Kang, "Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics", Clinical Psychopharmacology and Neuroscience, 19(1), pp.117~124 (2021), 대한정신약물학회[DOI]
2. Menezes NM, "A systematic review of longitudinal outcome studies of first-episode psychosis", Psychol Med, 36, pp.1349~1362 (2006)
3. Rofman ES, "Kaplan and Sadock’s synopsis of psychiatry: behavioral sciences", clinical psychiatry, 10th ed, 2009, pp.70, 10085~
4. Conley RR, "Evaluation of treatment-resistant schizophrenia", Schizophr Bull, 23, pp.663~674 (1997)
5. Friedman JI, "Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy", Neuropsychopharmacology, 36, pp.1289~1295 (2011)
6. Bahk WM, "Clinical Neuropsychopharmacology", pp.245~296 (2014), Sigma Press
7. Conley RR, "Management of treatment resistance in schizophrenia", Biol Psychiatry, 50, pp.898~911 (2001)
8. Altamura AC, "Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment", Int Clin Psychopharmacol, 22, pp.249~267 (2007)
9. Keepers GA, "The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia", Am J Psychiatry, 177, pp.868~872 (2020)
10. Hye Jin Choi, "Antipsychotics Prescribing Patterns of Patients with Schizophrenia Admitted to Korean General Hospital Psychiatric Unit: 2001 to 2008", Clinical Psychopharmacology and Neuroscience, 9(1), pp.17~22 (2011), 대한정신약물학회
11. 장진구, "일 대학병원 정신증 환자에서 항정신병약물 병용요법의 사용", 대한정신약물학회지, 24(2), pp.69~75 (2013), 대한정신약물학회
12. 최진영, "조현병 환자에서 항정신병약물 병용요법 분석 : 임상적관련인자 및 처방현황 조사", 신경정신의학, 53(6), pp.370~378 (2014), 대한신경정신의학회[DOI]
13. Hatta K, "Real-world effectiveness of antipsychotic monotherapy and polytherapy in 1543 patients with acute-phase schizophrenia", Asian J Psychiatr, 40, pp.82~87 (2019)
14. Srisurapanont M, "Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia : a systematic review and meta-analysis of randomized-controlled trials", J Psychiatr Res, 62, pp.38~47 (2015)
15. Paton C, "Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine : a meta-analysis", J Clin Psychopharmacol, 27, pp.198~204 (2007)
16. Galling B, "Antipsychotic augmentation vs. monotherapy in schizophrenia:systematic review, meta-analysis and meta-regression analysis", World Psychiatry, 16, pp.77~89 (2017)
17. Lerner V, "Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy", Clin Neuropharmacol, 28, pp.66~71 (2005)
18. Arora H, "An open label study on amisulpride in augmentation with atypical antipsychotics in treatment resistant patients of schizophrenia and schizoaffective disorders", Dehi Psychiatry Journal, 11, pp.83~88 (2008)
19. Barnes TRE, "Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial", Ther Adv Psychopharmacol, 8, pp.185~197 (2018)
20. Barnes TR, "Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness", Health Technol Assess, 21, pp.1~56 (2017)
21. Englisch S, "Quetiapine combined with amisulpride in schizophrenic patients with insufficient responses to quetiapine monotherapy", Clin Neuropharmacol, 33, pp.227~229 (2010)
22. Munro J, "Amisulpride augmentation of clozapine : an open non-randomized study in patients with schizophrenia partially responsive to clozapine", Acta Psychiatr Scand, 110, pp.292~298 (2004)
23. Molina JD, "Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine", Pharmacopsychiatry, 44, pp.142~147 (2011)
24. Schmidt-Kraepelin C, "Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial", Lancet Psychiatry, 9, pp.291~306 (2022)
25. Young Sup Woo, "Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study", Clinical Psychopharmacology and Neuroscience, 20(3), pp.567~572 (2022), 대한정신약물학회[DOI]
26. Schmidt-Kraepelin C, "Combination treatment with second generation antipsychotics other than clozapine", Eur Psychiatry, 64(S1), pp.S31~ (2021)
27. Chanpattana W, "Acute and maintenance ECT with flupenthixol in refractory schizophrenia: sustained improvements in psychopathology, quality of life, and social outcomes", Schizophr Res, 63, pp.189~193 (2003)
28. Chanpattana W, "Short-term effect of combined ECT and neuroleptic therapy in treatment-resistant schizophrenia", J ECT, 15, pp.129~139 (1999)
29. Leucht S, "Second-generation antipsychotics for schizophrenia : can we resolve the conflict?", Psychol Med, 39, pp.1591~1602 (2009)
30. Schmidt-Kraepelin C, "A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design", Eur Arch Psychiatry Clin Neurosci, 270, pp.83~94 (2020)
31. Toledo-Romero F, "Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy", Pharmacopsychiatry, 48, pp.51~57 (2015)
32. Genç Y, "Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study", Adv Ther, 24, pp.1~13 (2007)
33. Canadian Psychiatric Association, "Clinical practice guidelines. Treatment of schizophrenia", Can J Psychiatry, 50(13 Suppl 1), pp.7S~57S (2005)[DOI]
34. Lehman AF, "Practice guideline for the treatment of patients with schizophrenia, second edition", Am J Psychiatry, 161(2 Suppl), pp.1~56 (2004)
35. Nielsen J, "10-year trends in the treatment and outcomes of patients with first-episode schizophrenia", Acta Psychiatr Scand, 122, pp.356~366 (2010)
36. Gilmer TP, "Antipsychotic polypharmacy trends among medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004", Psychiatr Serv, 58, pp.1007~1010 (2007)
37. Christy J, "Combining antipsychotics; is this strategy useful?", Psychiatr Danub, 26(Suppl 1), pp.315~321 (2014)
38. Zarate CA Jr, "Algorithms for the treatment of schizophrenia", Psychopharmacol Bull, 31, pp.461~467 (1995)
39. Koshino Y, "Algorithm for treatment-refractory schizophrenia", Psychiatry Clin Neurosci, 53(Suppl), pp.S9~S13 (1999)
40. Freudenreich O, "Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations", Acta Psychiatr Scand, 106, pp.323~330 (2002)
41. National Collaborating Centre for Mental Health, "Psychosis and schizophrenia in adults: treatment and management" (2014), National Institute for Health and Care Excellence
42. Zink M, "Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine : a randomised controlled clinical trial", J Psychopharmacol, 23, pp.305~314 (2009)
43. Möller HJ, "Amisulpride : limbic specificity and the mechanism of antipsychotic atypicality", Prog Neuropsychopharmacol Biol Psychiatry, 27, pp.1101~1111 (2003)
44. Perrault G, "Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2", D3 dopamine receptor antagonist activity and limbic selectivity, 1997, pp.280, 73~82
45. Chivers JK, "Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors", J Pharm Pharmacol, 40, pp.415~421 (1988)

관련 논문AI추천